Comparison of vilanterol, a novel long-acting beta(2) agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

BACKGROUND: Current maintenance therapies for asthma require twice-daily dosing. Vilanterol (VI) is a novel long-acting beta(2) agonist, under development in combination with fluticasone furoate, a new inhaled corticosteroid (ICS). Findings from a previous 4-week study suggested that VI has inherent...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lötvall, Jan, Bateman, Eric D, Busse, William W, O’Byrne, Paul M, Woodcock, Ashley, Toler, William T, Jacques, Loretta, Goldfrad, Caroline, Bleecker, Eugene R
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4055937/
https://ncbi.nlm.nih.gov/pubmed/24928338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-5751-13-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados